Answers are grounded in this paper and cite their sources.
Policy viewpoint reviews FDA oncology decisions for refractory melanoma, highlighting potential negative impacts on US cancer drug development.
This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment.
No takes yet. Share an insight, caveat, or question.
Gilberto Lopes (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: